All In Biotech

Drug Trial Radar · NCT06645522

Safety and Efficacy of Edaravone Dexborneol for Acute Ischemic Stroke

Safety and Efficacy of Edaravone Dexborneol for Acute Ischemic Stroke: A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial

Last checked: Nov 20, 2026Latest source record: Oct 17, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 1,200 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

1,200

Planned (sponsor's estimate)

Start

Oct 30, 2024

Primary completion

Oct 30, 2026

Study completion Jan 30, 2027

Sponsor

Lead sponsor
Yi YangAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 17, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the efficacy and safety of edaravone dexborneol in treating acute ischemic stroke.

Conditions

  • Acute Ischemic Stroke

Interventions

  • Edaravone dexborneolDrug

    Edaravone dexborneol injection 37.5mg (edaravone 30mg and dexborneol 7.5mg) and 100ml of 0.9% saline every 12 hours for 7 days; sequentially a sublingual dose of edaravone dexborneol 36 mg (edaravone, 30 mg; dexborneol, 6 mg) twice a day for 21 days.

  • PlaceboDrug

    Placebo injection every 12 hours for 7 days; sequentially a sublingual dose of placebo drug twice a day for 21 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. modified rankin scale (mRS) score ≤ 1Time frame: Day 90 after randomization

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Hospital of Jilin University

    Changchun, Jilin, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.